Trinity Capital Provides $130MM in Growth Capital to Candel Therapeutics
Trinity Capital, an alternative asset manager, committed $130 million in growth capital to Candel Therapeutics, a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer. “As cancer incidence continues to rise, the need for truly transformative...
Read moreDetails









